NEW YORK, NY / ACCESSWIRE / December 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Geron Corp. (NASDAQ: GERN), MaxLinear Inc. (NYSE: MXL), Halozyme Therapeutics Inc. (NASDAQ: HALO) and Viavi Solutions Inc. (NASDAQ: VIAV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

To access our full PDF Research Packages for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

GERN Research Package: http://www.traders-choice.com/pdf?s=GERN

MXL Research Package: http://www.traders-choice.com/pdf?s=MXL

HALO Research Package: http://www.traders-choice.com/pdf?s=HALO

VIAV Research Package: http://www.traders-choice.com/pdf?s=VIAV

============

Highlights from today's reports include:

On Wednesday, December 9, 2015, Nasdaq Composite ended at 5,022.87, down 1.48%, Dow Jones Industrial Average declined 0.43%, to finish the day at 17,492.30, and the S&P 500 closed at 2,047.62, down 0.77%

- Geron Corp.'s stock slipped by 5.91% to close Wednesday's session at USD 4.46. The company's shares oscillated between USD 4.42 and USD 4.80. The stock recorded a trading volume of 3.30 million shares, which was above its 50-day daily average volume of 2.77 million shares and above its 52-week average volume of 3.01 million shares. Over the last five days, Geron Corp.'s shares have declined by 11.68% while in the past one month, the stock has gained a momentum of 14.36%. In addition, over the last three months, the stock has gained 38.08% and year to date, the shares have picked up 37.23%. The company has returned 12.34% in the past one month, and 32.34% in the past one year, on a compounded total return basis. The stock is at a price to book ratio of 5.07. The historical PB ratio is near to 3.91. Additionally, the stock is trading at a price to sales ratio of 20.64.

- MaxLinear Inc.'s stock declined 5.13% to close Wednesday's session at USD 16.29. The share price vacillated between USD 16.13 and USD 17.19. The stock recorded a trading volume of 0.87 million shares, which was below its 50-day daily average volume of 1.05 million shares and above its 52-week average volume of 0.55 million shares. Over the last three days MaxLinear Inc.'s shares have declined by 5.24% and in the past one week the stock has moved down 4.06%. However, in the last six months, the stock has gained 33.52% and year to date, the shares have picked up 119.84%. On a compounded total return basis, the company has returned 32.76% in the last half a year, and 106.20% in the past one year. The stock is at a price to book ratio of 3.99. The historical PB ratio is near to 2.83. Additionally, the stock is trading at a price to cash flow ratio of 28.92 and at a price to sales ratio of 4.02.

- Halozyme Therapeutics Inc.'s stock edged lower by 4.40% to close Wednesday's session at USD 16.29. The company's shares oscillated between USD 16.07 and USD 16.98. The stock recorded a trading volume of 0.87 million shares, which was below its 50-day daily average volume of 1.26 million shares and below its 52-week average volume of 1.52 million shares. Over the last three days, Halozyme Therapeutics Inc.'s shares have declined by 7.39% and in the past one week the shares have moved down 7.55%. However, year to date the stock has gained 68.81%. The stock is trading 3.64% below its 20-day simple moving average and 7.54% below its 200-day simple moving average. Further the stock is at a price to book ratio of 68.49. The historical PB ratio is near to 29.34. Moreover, Halozyme Therapeutics Inc.'s shares have a Relative Strength Index of 47.23.

- The stock of Viavi Solutions Inc. lost 1.30% to close Wednesday's session at USD 6.06. The shares of the company moved in the range of USD 5.95 and USD 6.21. A trading volume of 2.30 million shares was recorded, which was lower than its 150-day daily average volume of 3.28 million shares and below its 52-week average volume of 3.83 million shares. Over the last five days, Viavi Solutions Inc.'s shares have declined by 3.81% and in the past one month, the shares have lost 7.20%. Additionally, over the last three months, the stock has advanced 8.99% while in the past six months, the shares have registered a loss of 17.98%. Further the stock is having a 52 week range of USD 4.99 - USD 8.10. Moreover, Viavi Solutions Inc.?s stock is trading 3.42% below its 20-day simple moving average and 8.17% below its 200 day simple moving average.

About Trader's Choice:

Trader's Choice ("TC") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
E-mail: press (at) traders-choice.com

SOURCE: Trader's Choice